Bunnik, the Netherlands, February 2, 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, announced today the appointment of Bart Wuurman, M. Sc. as Chief Executive Officer.
Bart Wuurman, M. Sc. replaces Bruno Giannetti, MD., Ph.D., who left AM-Pharma in December 2006. Bart Wuurman has 18 years of International Pharma and Biotechnology Industry experience with Organon, Medeva and Antisoma, where he was responsible for a $500 million oncology alliance with Roche. In 2003 Bart became CEO of De Novo Pharmaceuticals in Cambridge, UK, where he successfully implemented a restructuring and refinancing strategy.
Bart Wuurman, M. Sc., CEO of AM-Pharma comments: “With its two innovative products in Phase II, promising clinical data and a healthy financial position, AM-Pharma stands out in the EU biotech arena. I am very happy with my appointment because AM-Pharma presents a great opportunity for strong short term value growth.”
Prof. Eric Claassen, Chairman of AM-Pharma comments: “We are very excited about the appointment of Bart Wuurman. He brings a wealth of biotechnology experience, a commercial focus and a relevant international network, which is exactly what AM-Pharma needs now that its products are generating such exciting clinical results.”
More Information:
AM-Pharma is a biopharmaceutical company based in Bunnik, the Netherlands. The
company is focused on the preclinical and clinical development of novel compounds
in the field of severe infectious diseases and inflammatory diseases.
AM-Pharma is currently conducting Phase II clinical trials on two products; Alkaline Phosphatase for Sepsis and Inflammatory Bowel Disease and hLF1-11, an Anti-Microbial Peptide for the prevention of infections in Hemopoietic Stem Cell Transplant patients.
AM-Pharma employs 20 staff and is financed by amongst others Forbion Capital Partners and Inventages Venture Capital.
For further information about AM-Pharma, please visit the company's website at www.AM-Pharma.com.